Investigational drug · Phase 3
Mazdutide
Also called: LY3305677
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes, Obesity, Overweight.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
3 still active
All registered trials
44
Any phase or sponsor naming "Mazdutide"
First trial start
2023
Nov 17, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Mazdutide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes
- Obesity
- Overweight
- Alcohol Use Disorder
- Overweight and Obesity
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Alcohol dependence · Cardiovascular and metabolic · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "Mazdutide" as an intervention, largest first.
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06143956 · 1,481 participants (planned) · Start Nov 17, 2023 · Primary completion Sep 2027
Drug: LY3305677; LY3841136 and 5 more · For: Obesity; Overweight
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 57 sites in all
- A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) InhibitorPivotal-lookingNot yet recruiting
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
NCT07417306 · 912 participants (planned) · Start Mar 27, 2026 · Primary completion Aug 30, 2027
Drug: HDM1005 1; HDM1005 2 and 1 more · For: Type 2 Diabetes
Sites: Beijing, China
- QUARTET-DKD: Quadruple Therapy for Type 2 Diabetic NephropathyPivotal-lookingRecruiting
Huijie ZhangAcademic, hospital or other
NCT07775846 · 820 participants (planned) · Start Nov 3, 2026 · Primary completion Feb 28, 2029
Drug: empagliflozin; Finerenone and 4 more · For: Type 2 Diabetic Kidney Disease
Sites: Shanghai, China
- A Study of IBI362 in Participants With Type 2 DiabetesPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05606913 · 731 participants · Start Jan 6, 2023 · Primary completion Jan 26, 2024
Drug: dulaglutide; IBI362 · For: Type 2 Diabetes
Sites: Beijing, China
- Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese PatientsPivotal-lookingNot yet recruiting
Beijing Anzhen HospitalAcademic, hospital or other
NCT07897305 · 700 participants (planned) · Start Oct 25, 2026 · Primary completion Dec 30, 2028
Drug: Mazdutide · For: Atrial Fibrillation (AF); Ablation Treatment; Obesity & Overweight and 1 more
Sites: Beijing, China
- A Study of IBI362 in Participants With Obesity or OverweightPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05607680 · 610 participants · Start Nov 14, 2022 · Primary completion Aug 21, 2023
Drug: Placebo; IBI362 · For: Obesity Or Overweight
Sites: Xuancheng, China; Beijing, China; Luoyang, China · 23 sites in all
- A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)Pivotal-lookingActive, not recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06884293 · 479 participants · Start May 9, 2025 · Primary completion Dec 31, 2026
Drug: IBI362; semaglutide · For: Overweight; Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
Sites: Beijing, China
- A Study of IBI362 9 mg in Chinese Adults With ObesityPivotal-lookingStatus unknown
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06164873 · 462 participants · Start Dec 27, 2023 · Primary completion Jun 27, 2025
Drug: IBI362; Placebo · For: Obesity
Sites: Beijing, China
- ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight ManagementPivotal-lookingRecruiting
Shanghai Zhongshan HospitalAcademic, hospital or other
NCT07517042 · 420 participants (planned) · Start Jun 10, 2026 · Primary completion Dec 2028
Drug: Mazdutide; Mazdutide Placebo · For: Obesity; Weight Control
Sites: Fuzhou, China; Xiamen, China; Guiyang, China · 21 sites in all
- Mazdutide in Type 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)Pivotal-lookingRecruiting
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAcademic, hospital or other
NCT07083154 · 420 participants (planned) · Start Sep 27, 2025 · Primary completion Aug 1, 2029
Drug: Mazdutide; Placebo · For: Dementia, Mild; Mild Cognitive Impairment; Type 2 Diabetes
Sites: Changsha, China; Changzhou, China; Nanjing, China · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications.
Chen Z, Zhou Y, Li G, et al. · J Diabetes Metab Disord 2026
- Efficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Amjad MM, Khan MM, Sarwar F, et al. · Diabetes Obes Metab 2026
- Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomised, placebo-controlled clinical trial.
Hsia SH, Bays HE, Billings LK, et al. · Lancet Diabetes Endocrinol 2026
- From Oxyntomodulin to Retatrutide: A Translational Review of Metabolic Polyagonism.
Saldívar-Cerón HI, Maldonado-Trejo D, Chavez-Castañeda Q, et al. · Int J Mol Sci 2026
- Effectiveness of the Dual GLP-1R/GCGR Agonist Mazdutide in GSD IXc: A Case Report.
Chen Y, Zhong X, Guo X, et al. · J Clin Med 2026
- The GLP-1R/GCGR Dual Agonist Mazdutide Attenuates Liver Steatosis and Decreases Circulating Cholesterol Levels in Mice With Metabolic Dysfunction-Associated Steatotic Liver Disease.
Yu L, Wang G, Zhang J, et al. · Diabetes Obes Metab 2026
Also in development for Type 2 Diabetes
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.